Cizzle Biotechnology Holdings PLC (GB:CIZ) has released an update.
Cizzle Biotechnology Holdings PLC is advancing in the field of lung cancer diagnostics with a strategic partnership in North America and an extended research agreement with the University of York for clinical evaluation in the US. The company has received a $100,000 upfront payment and expects a further $300,000 upon signing a binding agreement, which will also secure them a 10% stake in their US partner, BIO. With a major US cancer center selecting their CIZ1B biomarker test for a significant clinical study, Cizzle Biotechnology is on track to launch its early detection blood test by 2025, potentially transforming lung cancer diagnostics.
For further insights into GB:CIZ stock, check out TipRanks’ Stock Analysis page.
